Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure

Jose Ángel Fernández-Caballero 1,2*, Natalia Chueca 1, Marta Álvarez 1, María Dolores Mérida 1, Josefa López 1, José Antonio Sánchez 1, David Vinuesa 1, María Angeles Martínez 1, José Hernández 1 and Federico García 1

Abstract

Background: In our study, we have hypothesized that proviral DNA may show the history of mutations that emerged at previous failures to a Raltegravir containing regimen, in patients who are currently undetectable and candidates to simplification to a Dolutegravir containing regimen, in order to decide on once a day or twice a day dosing.

Methods: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. After an average (IQR) time of 48 months (29–53) Integrase resistance mutations in proviral DNA were studied.

Results: All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. Median viral load (log) and CD4 count at the moment of the study on proviral DNA was of 1.3 log cp/ml (range 0–1.47) and 765.5 cells/μL (range; 436.75–1023.75). The median time (IQR) between previous failure to RAL and the study on proviral DNA was 48 (29–53) months. At Raltegravir failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient. Sanger sequencing correctly identified all the secondary mutations.

Conclusion: This is a pilot study that demonstrates the possibility of properly identifying N155H and some secondary mutations 29–53 months after failure.

Keywords: HIV, Integrase, Proviral DNA, Raltegravir, Dolutegravir

Background

For the last 6 years, Raltegravir (RAL), the first strand Integrase transfer inhibitor (INIs) approved, has played a relevant role on the treatment of HIV infection, both for naive and pretreated patients [1].

Nowadays, Elvitegravir (EVG) and Dolutegravir (DTG), two new INIs have become available. EVG is a first generation drug and shares its resistance profile with RAL, whereas DTG is a second generation INI with a high antiviral effect, and excellent efficacy and safety profile. Although DTG has a high genetic barrier to resistance, its activity may be limited by certain combination of resistance mutations that may accumulate during failure to RAL [2]. The occurrence of these mutations is not frequent [3] and the use of DTG to salvage patients who have developed resistance to RAL has been well studied and documented [4, 5]. DTG has a long plasmatic half-life, so it can be dosed once a day (QD) on patients without pre-existent resistance to INIs; if the patient to be treated is infected by viruses carrying any resistance mutation to INIs, then DTG has to be dosed twice a day [6, 7] (BID). If
the resistance profile at failure was not documented, patients with a prior failure to RAL need to be treated BID, as this is the safest approach.

In our study, we have hypothesized that proviral DNA may show the history of mutations that emerged at failure to RAL, and we attempted to provide the proof of concept that testing proviral DNA may be used as a sentinel for RAL mutations, in patients who are currently undetectable and candidates to simplification to a DTG containing regimen.

Methods
We have performed a pilot, observational, retrospective, non-interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. After an average (IQR) time of 48 months (29–53), Integrase resistance mutations in proviral DNA were studied.

Peripheral Blood Mononuclear Cells (PBMC) were separated by Ficoll gradient centrifugation, washed, counted and pelleted to 5x10⁶ leukocytes aliquots, that were used for DNA extraction with QIAamp DSP Blood Mini Kit (QIAGEN). DNA was quantified by spectrophotometry (NanoDrop, ThermoScientific).

Integrase was amplified using a nested-PCR. For the first round of amplification, we used outer primers IN1F (5’-GGAAAGGTCTACCTGTACATGGGT-3’) and IN1R (5’-GGAGAAAGAGACTGGCATTTGG-3’) and the following PCR profile: 94 °C/2’; (94 °C/15’; 60 °C/30’; 72 °C/45’) x35 cycles; 72 °C/7’; 4 °C. This profile was used for the nested PCR, using inner primers INR2F (5’-TGGAGGAATGAAACATGAAATT-3’) and (INT2R: 5’-GGGTCTGCATACAGGAGAAA-3’).

For Sanger sequencing, we used a bidirectional sequencing protocol and the Thermo Sequenase Dye Primer Manual Cycle Sequencing Kit (Affymetrix USB), which was optimized for the TruGene/OpenGene DNA sequencing system (SIEMENS); sequencing primers were P1F:5’-Cy5.5-GTAGCCAGCTGTGATAAATGTC-3’ and P2R (5’-Cy5-CTGCCATTTTGTACTGCTGTCT-3’), allowing to sequence 414 nucleotides in the Integrase region, covering positions 40 to 178. The amplification profile was: 94 °C/5’; (94 °C/20’; 62 °C/20’; 72 °C/2’) x30 cycles; 70 °C/5’; 4 °C. The obtained sequences were aligned and combined using OpenGene Geneobjects™ software, and fasta sequences were interpreted Stanford HIV Database Versión 7.0 [8].

Ultra Deep Sequencing (UDS) was done using an HIV-1 UDS prototype (Roche diagnostics) and the 454 GS Junior (Roche 454 Life Sciences Branford, CT). As template for the UDS PCR, we used the same amplification products as for standard Sanger sequencing following from this point the manufacturer’s recommendations. Once UDS was performed, sequences were exported by AVA (GS Amplicon Variant Analyzer, Roche) software and interpreted by DeepChek® VIH (ABL, SA) software, using for interpretation the same Stanford version as for Sanger sequencing.

This was a retrospective, non-interventional study, and patient information was anonymized and de-identified prior to analysis.

Results
All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. Median viral load (log) and CD4 count at the moment of the study on proviral DNA was 1.3 log cp/ml (range 0–1.47) and 765.5 cells/μl (range; 436.75-1023.75). The median time (IQR) between previous failure to RAL and the study on proviral DNA was 48 (29–53) months. Detailed information on baseline characteristics is shown in Table 1.

Table 1 shows the correlation on resistance mutations (Sanger sequencing) detected at RAL failure in plasma and on proviral DNA, after a median period of 48 months of being undetectable. At failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient. Sanger sequencing correctly identified all the secondary mutations. We observed that proviral DNA and plasma RNA drug resistance mutations and polymorphisms were highly concordant.

Discussion
Dolutegravir has shown excellent efficacy and safety in individuals infected by HIV both in naïve [9], and patients with prior exposure to RAL [10]. Only the accumulation of Q148H/R/K, together with other secondary mutations broadens DTG activity [11]. The VIKING

| Patient | Date of failure | Age | CD4 | VL (log) | Time (months) |
|---------|----------------|-----|-----|----------|---------------|
| 1       | 15/10/2009     | 56  | NR  | ND       | 21            |
| 2       | 20/10/2009     | 56  | 484 | 1.47     | 53            |
| 3       | 01/10/2009     | 59  | 670 | 1.30     | 52            |
| 4       | 17/02/2011     | 39  | 1365| 1.47     | 36            |
| 5       | 02/03/2010     | 51  | 910 | 1.30     | 48            |
| 6       | 26/10/2012     | 43  | 295 | 2.74     | 29            |
| 7       | 13/8/2009      | 55  | 861 | ND       | 56            |

Viral load (VL) is in the actual moment. (NR Not recorded, ND Not detectable)
study evaluated Dolutegravir dosing, demonstrating a higher efficacy, tolerability and safety when dosing DTG 50 mg [10] twice a day (BID) for patients with resistance mutations in the Integrase. While BID is the safest approach, DTG is only recommended 50 mg once a day (QD) for patients with no resistance against Integrase inhibitors. For some patients who have not been tested for Integrase resistance at failure, and have been effectively suppressed with a new antiretroviral regimen, BID remains the safest dosing strategy, but QD could possibly play a role, reducing the cost of the new regimen.

Proviral DNA may be a useful tool to investigate the presence of resistance mutations [12–14], especially in patients who as a consequence of antiretroviral therapy are virologically suppressed.

In our study, using Sanger sequencing of the Integrase region of proviral DNA, we could correctly identify failing selected mutations in 6/7 patients. Although for the remaining patient we could not demonstrate the failing mutation with Sanger sequencing, using a more sensitive test [15], resulted in the correct identification of the failing mutations [N155H (9.7 %) and T97A (12.42 %)] suggesting that, given the superiority of massive parallel sequencing, this should be the tool recommended for testing proviral DNA in virologically suppressed patients, although at present it is an expensive tool that may not be feasible in some laboratories.

Although the sampling time in patients 2, 3 & 7 exceeded the half-life of the HIV-1 reservoir, this did not interfere in the correlation between the failing sample and proviral DNA testing. Despite some studies have demonstrated that the latent viral reservoirs half-life is from four to six months in patients who start therapy in the acute infection stage, there are other studies in chronically infected patients who have shown a half-time of 44 months [16, 17].

Our study has certain limitations. First, only subtype B patients have been included, so the methodology needs to be validated for other subtypes. Secondly, only the N155H pathway was confirmed in some patients and it is possible that resistance pathways other than N155H, that could have emerged before N155H was established, may have been archived in the proviral DNA of the patients compromising DTG activity.

Conclusions
In summary, despite the limitations of our study, which is just a pilot study that should be confirmed in further studies, we have shown the proof of concept that for patients who failed a Raltegravir containing regimen in the past, who are currently virologically suppressed, and lack the resistance information at failure, studying Integrase resistance in the proviral DNA accurately reflects the possibility of properly identifying N155H and some secondary mutations 29–53 months after failure.

Ethics approval
The Ethics Committee of the San Cecilio Hospital approved the study, and no consent information was required as patient information was anonymised and de-identified prior to analyses.

Consent for publication
Not applicable.

Availability of data and materials
All data supporting our findings is contained within the manuscript.

Abbreviations
AVA: amplicon variant analyzer; BID: twice a day; DNA: deoxyribonucleic acid; DTG: Dolutegravir; EVG: Elvitegravir; HIV: human immunodeficiency virus; INIs: strand integrase inhibitor; IQR: interquartile range; PBMC: peripheral blood mononuclear cells; PCR: polymerase chain reaction; QD: once a day; RAL: Raltegravir; UDS: ultra deep sequencing.

| Table 2 Primary and secondary resistance mutations in the Integrase by Sanger population sequencing |
|------------------|------------------|------------------|
| Patient | Major resistance mutation | Accessory mutation | Polymorphism mutation |
| 1F | N155H | — | CS65, E85EG, L101I, S119P, T122I, H171Q, K173EK |
| 1A | N155H | — | CS65, L101I, S119P, T122I, H171Q |
| 2F | N155H | — | MS0l, L68R, V71I, L101I, S119P, H171Q |
| 2A | N155H | — | MS0l, V71I, P90PS, L101I, S119P |
| 3F | — | L74I | E96D, K111T, K160KT |
| 3A | — | L74I | E96D, K111T, G123RS |
| 4F | — | G163GR | L101I, I113V, G134E, V150AV |
| 4A | — | G163GR | MS0lM, L101I, I113V, V150A |
| 5F | — | L74IM | MS0l, V72l, K103R, K111T, A124T |
| 5A | — | L74I | MS0l, V72l, K103R, K111T |
| 6F | N155H | T97A | D55Y, V72l, K111T, I113V, S119R, G123S, A124N, T125A |
| 6A | — | — | V72l, K111T, I113V, S119R, G123S, A124N, T125A |
| 6 UDS | N155H (9.77 %) | T97A (12.42 %) | V72l(37.44 %), Y99C(4.65 %), T122l(12.56 %), K156N(14.35 %), E157A(15.35 %), K111T(29.3 %), I113V(29.3 %), S119R(37.4 %), G123S(97.21 %), A124N(43.26 %), T125A(45.58 %) |
| 7F | N155H | V151I | I113V, S119P, T122l, A124N, C130Y |
| 7A | N155H | V151I | G52P, S119PR, T122l, I161X |

Patients are indicated with the numbers 1 to 7; F relates to the time point of therapeutic failure (plasma RNA), A to the proviral DNA studies after virological suppression, and UDS to massive sequencing data.
Competing interests
The authors declare that they have no competing interests.

Authors' contributions
FG and JAF took part in the design of the study and drafted the manuscript. FG made substantial contributions to analysis and interpretation of data. NC, MA and JAF participated in the sequence alignment. MDM, JL and JAS helped with the sequencing and data analysis. DV, MAM and JH helped with data acquisition. All authors read and approved the final manuscript.

Acknowledgements
We are grateful to all the patients who participated in the study for their contribution.

Funding
This study was funded by Fondo de Investigación Sanitaria (PI12/01053, PI15/00713), RD12/0017/006 (Plan Nacional de I + D + I, Fondo Europeo de Desarrollo Regional-FEDER).

Received: 18 December 2015 Accepted: 5 May 2016
Published online: 13 May 2016

References
1. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85.
2. Carganico A, Dupke S, Ehret R, Berg T, Baumgarten A, Obermeier M, et al. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19749.
3. Codóñer FM, Pou C, Thielen A, Garcia F, Delgado R, Dalmau D, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res. 2013;98(3):291–5.
4. Blanco JL, Martinez-Picado J. HIV Integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS. 2012;7(5):415–21.
5. Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients-Impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 2011;90(3):164–7.
6. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012;21(4):523–30.
7. Rathbun RC, Lockhart SM, Miller MM, Liedtke MD. Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection. Ann Pharmacother. 2014;48(3):395–403.
8. Stanford HIV Database Version 7.0. http://hivdb.stanford.edu/. Accessed 05 Dec 2015.
9. Van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a doseranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
10. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207(5):740–8.
11. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–62.
12. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol. 2005;33(3):206–16.
13. Gouveia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009;49(4):462–72.
14. MacLeod IJ, Rowley CF, Thorl I, Wester C, MakHEMA J, Essex M, et al. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol. 2010;48(3):162–7.
15. García F, Álvarez M, Bernal C, Chueca N, Guillot V. Laboratory diagnosis of HIV infection, viral tropism and resistance to antiretrovirals. Enferm Microbiol Clin. 2011;29(4):297–307.
16. Quercia R, Dann E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 Integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol. 2009;83(19):10245–9.
17. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Veranen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605–13.